-
Biogen International GmbH et al v. Hetero USA Inc. et al DC CAFC
- 1:17-cv-00825
- D. Del.
- Judge: Maryellen Noreika
- Filed: 06/26/2017
- Closed: 09/22/2020
- Latest Docket Entry: 10/31/2022
- PACER
2
Plaintiffs
3
Defendants
2
Accused
Products
3
Patents-in-Suit
1,185
Days in
Litigation
-
Biogen International GmbH et al v. Hetero USA Inc. et al DC CAFC
- 1:17-cv-00825
- D. Del.
- Judge: Maryellen Noreika
- Filed: 06/26/2017
- Closed: 09/22/2020
- Latest Docket Entry: 10/31/2022
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject in need thereof a pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl
view more
|
Invalid
Entry 18 |
| 2 |
The method of claim 1, wherein the pharmaceutical composition is administered in the form of a tablet, a suspension, or a capsule.
|
Invalid
Entry 18 |
| 3 |
The method of claim 1, wherein the therapeutically effective amount is administered in separate administrations of 2, 3, 4, or 6 equal doses.
|
Invalid
Entry 18 |
| 4 |
The method of claim 3, wherein the therapeutically effective amount is administered in separate administrations of 2 equal doses.
|
Invalid
Entry 18 |
| 6 |
The method of claim 1, wherein the pharmaceutical composition consists essentially of dimethyl fumarate and one or more pharmaceutically acceptable excipients.
|
Invalid
Entry 18 |
| 8 |
The method of claim 1, wherein the pharmaceutical composition is administered to the subject for at least 12 weeks.
|
Invalid
Entry 18 |
| 9 |
The method of claim 6, wherein the therapeutically effective amount is administered to the subject in 2 equal doses.
|
Invalid
Entry 18 |
| 10 |
The method of claim 9, wherein the therapeutically effective amount is administered to the subject for at least 12 weeks.
|
Invalid
Entry 18 |
| 11 |
A method of treating a subject in need of treatment for multiple sclerosis consisting essentially of orally administering to the subject about 480 mg per day of dimethyl fumarate, monomethyl fumarate, or a combination thereof.
|
Invalid
Entry 18 |
| 12 |
The method of claim 11, wherein about 480 mg of dimethyl fumarate per day is administered to the subject.
|
Invalid
Entry 18 |
| 13 |
The method of claim 12, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses.
|
Invalid
Entry 18 |
| 15 |
A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate and (b) one or
view more
|
Invalid
Entry 18 |
| 16 |
The method of claim 15, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses.
|
Invalid
Entry 18 |